<h4>Aims</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real-world effects in individuals with obesity without diabetes are unclear. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.